Cell & Gene Therapy Innovation Speaker
Dr. Katherine Seidl earned a Ph.D. in Genetics (1996) from Stanford University, under the supervision of Drs. Len and Lee Herzenberg studying B cell development and immunoglobulin repertoire. After postdoctoral training at Harvard Medical School (1996-2000) under the guidance of Dr. Frederick Alt studying B cell immunoglobulin VDJ and class switch recombination, Dr. Seidl embarked on a 15+ year career in drug discovery and development. Since June 2016, Dr. Seidlhas served as Director, Oncology, at bluebird bio, Cambridge, MA. Dr. Seidl was formerly with Novartis Institute of Biomedical Research in Basel, Switzerland and Cambridge, MA , USA where she held several positions with increasing responsibility over a nearly 6 year tenure.